Hydrogen-Bonding-Mediated Anthranilamide Homoduplexes. Increasing Stability through Preorganization and Iterative Arrangement of a Simple Amide Binding Site
摘要:
This paper describes the assembly of two new series of self-complementary duplexes by making use of amide units, the simplest assembling units of hydrogen bonding, as binding sites. All the new monomers possess a rigidified anthranilamide skeleton, which is stabilized by intramolecular hydrogen bonding. Amide units are iteratively introduced to one side of the preorganized skeletons to facilitate the formation of intermolecular hydrogen bonding. Compounds 2 and 3 bear two and three CONH2 units, respectively, while 4, 6, and 7 are incorporated with two, three, and four AcNH units, respectively. For comparison, compound 5, which is similar to 4 but contains one AcNH and one CF3CONH unit, is also prepared. X-ray diffraction analysis of 2, 4, and 5 revealed homodimeric motifs in the solid state which are stabilized by two or more intermolecular hydrogen bonds. H-1 NMR investigations in CDCl3 indicated that all the compounds form hydrogen-bonded homoduplexes. Duplexes 3(.)3, 6(.)6, and 7(.)7 are highly stable in CDCl3, with a lower K-assoc limit of 2.3 x 10(5) M-1. The K-assoc values of the three duplexes in more polar CDCl3/CD3CN (9:1, v/v) were determined with the H-1 NMR dilution method. The result opens the way for the development of new polymeric duplexes of well-ordered structures.
Hydrogen-Bonding-Mediated Anthranilamide Homoduplexes. Increasing Stability through Preorganization and Iterative Arrangement of a Simple Amide Binding Site
摘要:
This paper describes the assembly of two new series of self-complementary duplexes by making use of amide units, the simplest assembling units of hydrogen bonding, as binding sites. All the new monomers possess a rigidified anthranilamide skeleton, which is stabilized by intramolecular hydrogen bonding. Amide units are iteratively introduced to one side of the preorganized skeletons to facilitate the formation of intermolecular hydrogen bonding. Compounds 2 and 3 bear two and three CONH2 units, respectively, while 4, 6, and 7 are incorporated with two, three, and four AcNH units, respectively. For comparison, compound 5, which is similar to 4 but contains one AcNH and one CF3CONH unit, is also prepared. X-ray diffraction analysis of 2, 4, and 5 revealed homodimeric motifs in the solid state which are stabilized by two or more intermolecular hydrogen bonds. H-1 NMR investigations in CDCl3 indicated that all the compounds form hydrogen-bonded homoduplexes. Duplexes 3(.)3, 6(.)6, and 7(.)7 are highly stable in CDCl3, with a lower K-assoc limit of 2.3 x 10(5) M-1. The K-assoc values of the three duplexes in more polar CDCl3/CD3CN (9:1, v/v) were determined with the H-1 NMR dilution method. The result opens the way for the development of new polymeric duplexes of well-ordered structures.
Hydrogen-Bonding-Mediated Dynamic Covalent Synthesis of Macrocycles and Capsules: New Receptors for Aliphatic Ammonium Ions and the Formation of Pseudo[3]rotaxanes
作者:Xiao-Na Xu、Lu Wang、Gui-Tao Wang、Jian-Bin Lin、Guang-Yu Li、Xi-Kui Jiang、Zhan-Ting Li
DOI:10.1002/chem.200900309
日期:2009.6.2
Dynamiccovalentsynthesis! Intramolecular hydrogen‐bonding induces amino‐ and aldehyde‐appended aryl amides to adopt a rigid “V”‐shaped conformation. As a result, stable two‐layered capsules can be assembled quantitatively through the one‐step formation of six imine bonds. The newcapsules form complexes with aliphatic diammonium ions to give unique two‐layered pseudo[3]rotaxanes (see figure).
Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
[EN] FXR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEUR DE FARNESOIDE X
申请人:LILLY CO ELI
公开号:WO2007140183A1
公开(公告)日:2007-12-06
[EN] Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. [FR] L'invention concerne des composés de la formule dans laquelle des variables sont telles que définies dans le descriptif, ainsi que leurs compositions pharmaceutiques et leurs procédés d'utilisation pour le traitement de la dyslipidémie et de maladies connexes.